Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average recommendation of “Buy” by the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $11.50.

Several equities research analysts recently issued reports on CATX shares. Bank of America decreased their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday. Piper Sandler lowered their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, BMO Capital Markets set a $11.00 price objective on Perspective Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 18th.

Perspective Therapeutics Trading Down 1.1%

Perspective Therapeutics stock opened at $2.70 on Friday. The stock has a fifty day moving average price of $3.05 and a 200 day moving average price of $3.68. Perspective Therapeutics has a 52 week low of $1.96 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%.The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. On average, analysts anticipate that Perspective Therapeutics will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Abel Hall LLC purchased a new position in shares of Perspective Therapeutics in the 1st quarter worth about $49,000. AXQ Capital LP increased its position in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Perspective Therapeutics during the 4th quarter worth approximately $84,000. Wealth Effects LLC raised its holdings in Perspective Therapeutics by 32.0% in the first quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after buying an additional 8,000 shares during the period. Finally, Quantinno Capital Management LP purchased a new position in Perspective Therapeutics in the first quarter valued at approximately $273,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.